Pay with Crypto and get 10% off your order!
LabCorp

High Molecular Weight Kininogen (HMWK / Fitzgerald Factor)

$218.00
5413
500460
Only 100 units of this product remain
Phlebotomy (IV Blood Draw)

Useful in the evaluation of an elevated APTT. Measurement of high molecular weight kinonogen concentration.

High molecular weight kininogen (HMWK) is a 110 kilodalton single-chain nonenzymatic cofactor synthesized in the liver which is central to contact activation reactions.6 It forms a complex with prekallikrein and factor XI. HMWK's plasma concentration is 70 mg/mL and its plasma half-life is approximately 144 hours. Factors VIII, IX, XI, XII, prekallikrein, and HMWK are the coagulation factors of the intrinsic coagulation pathway. Factor XII, high molecular weight kininogen, and prekallikrein are also called the “contact” factors. Factor XI is sometimes included in this designate of “contact” factors because of its interaction with others listed. Factor XI is activated by factor XIIa formed through activation of XII by HMWK-prekallikrein complex on endothelial cells. HMWK proteolysis leads to the production of bradykinin, a mediator of vasodilation, smooth muscle contractions, and increased vascular permeability. Other functions of HMWK include inhibition of thrombin-induced platelet aggregation, participant in fibrinolysis, as well as having surface-binding antiadhesive properties. Contact factor deficiencies have no hemorrhagic consequence; however, the contact factors are necessary for normal aPTT clot formation in the laboratory. Deficiency of HMWK produces markedly prolongs aPTT results. Hereditary HMWK deficiency conditions are inherited through an autosomal recessive pattern. Although the aPTT is prolonged in deficiencies of factor XII, prekallikrein, and high molecular weight kininogen, there is generally no clinical evidence of bleeding unless other contributing factors are present. These deficiencies are generally diagnosed when evaluating a prolonged aPTT with no other explanation (ie, other screening tests) and clinical history is negative for a bleeding disorder.

1. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997 Jan; 107(1):105-110. PubMed 8980376

2. Reneke J, Etzell J, Leslie S, Ng VL, Gottfried EL. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998 Jun; 109(6):754-757. PubMed 9620035

3. National Committee for Clinical Laboratory Standardization. Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline. 5th ed.. Villanova, Pa: NCCLS; 2008. Document H21-A5:28(5).

4. Gottfried EL, Adachi MM. Prothrombin time and activated partial thromboplastin time can be performed on the first tube. Am J Clin Pathol. 1997 Jun; 107(6):681-683. PubMed 9169665

5. McGlasson DL, More L, Best HA, Norris WL, Doe RH, Ray H. Drawing specimens for coagulation testing: Is a second tube necessary? Clin Lab Sci. 1999 May-Jun; 12(3):137-139. PubMed 10539100

6. Adcock DM, Bethel MA, Macy PA. Coagulation Handbook.
Aurora, Colo: Esoterix−Colorado Coagulation; 2006.

You might also be interested in